Sarah Hamm-Alvarez, PhD: Could Tears Hold a Parkinson Biomarker?
It’s difficult to diagnose Parkinson disease before some permanent neurological damage occurs. But tears may hold the key to earlier diagnoses.
Concussion-Related Visual Dysfunction Linked to Longer Recovery Time
Investigators found that children who experienced concussion-related visual dysfunction had a recovery time nearly twice that of those who did not.
William Freeman, MD: Creating Treatments with Compliance in Mind
William Freeman, MD, of UCSD and Shiley Eye Institute, discusses the importance of creating treatments for eye diseases that make compliance easier for patients.
William Freeman, MD: Brimonidine as a Treatment for Geographic Atrophy
William Freeman, MD, discusses the results of a study he led and other potential treatments for geographic atrophy from a session he hosted at ARVO 2019.
Pinakin Davey, DO, PhD: Novel Methods for Testing IOP
Pinakin Davey, DO, PhD, sat down with MD Magazine® at ARVO 2019 to discuss a study he led testing a handheld tonometer for testing IOP.
Jennifer Lim, MD: Results of the EyeArt Diabetic Retinopathy Screening Study
The artificial intelligence system, EyeArt, was able to detect diabetic retinopathy with a sensitivity of 95.5% and specificity of 86%.
Jonathan Myers, MD: When Should Patients with Worsening Vision Stop Driving?
Jonathan Myers, MD, of the Wills Eye Hospital, discusses a study examining the rate of car accidents among glaucoma patients.
Jennifer Lim, MD: Training & Testing AI to Detect Diabetic Retinopathy
After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.
Jennifer Lim, MD: Can AI Fill the Gap in Diabetic Retinopathy Screening?
With 8.5% of the global population having diabetes, there is a growing unmet need for diabetic retinopathy screening. Artificial intelligence may help close the gap.
Charles Wykoff, MD, PhD: Results & Implications of the PANORAMA Trial
Aflibercept not only significantly improved patients’ DRSS scores, but it also reduced vision-threatening complications by 75% compared to placebo.
Charles Wykoff, MD, PhD: PANORAMA Trial Design & Patients
The trial examined 2 doses of aflibercept versus sham in patients with good visual acuity and no center-involving diabetic macular edema.
Switching to Intravitreal Aflibercept from other Anti-VEGF treatments
Investigators reported improvements in BCVA and in central subfield thickness, but noted decreases in superficial and deep capillary density.
No Benefit to Beginning Treatment Prior to Vision Loss in Most DME Cases
A recent study found that early intervention before vision loss does little for patients compared to those who do not receive preemptive treatment.
Charles Wykoff, MD, PhD: Context of the PANORAMA Trial
PANORAMA is the first prospective study of high-risk patients with non-proliferative diabetic retinopathy, but not DME, in the anti-VEGF era.
Association Between Chronic Conditions and Visual Impairment
After analyzing information from a cohort of more than 380,000, investigators found an association between chronic illnesses and visual impairment.
Increasing Awareness & Screening Efforts Against Diabetic Keratopathy
Approximately half of all patients with diabetes suffer from keratopathy, yet diagnoses are still underwhelming. Annual screenings need to become more standard.
Jason Hsu, MD: Outcomes of Switching from Aflibercept to Ranibizumab
Jason Hsu, MD, and his colleagues at the Wills Eye Hospital presented a study at ARVO 2019 regarding short-term outcomes of patients, with nAMD, who switched from afliberecept to ranibizumab.
Mia Woodward, MD: The Role of Telehealth in Ophthalmology
Mia Woodward, MD, discusses the future of telehealth in ophthalmology and the biggest issues that need to be corrected going forward.
Vivek Patel, MD: Retinal Pathology and Alterations in the Brain
Researchers are using hi-def retinal and neuroimaging techniques to elucidate the relationship between pathology in layers of the retina and downstream brain alterations.
Hossein Ameri, MD: Will CRISPR Fix Retinitis Pigmentosa?
Following the novel gene-editing tech's approval for the treatment of cancer last year, researchers at Roski Eye Institute are exploring its potential to treat ophthalmic disease.
Lan Yue, PhD: Will Nanophotoswitches One Day Restore Sight to the Blind?
Nanophotoswitches have demonstrated promising results in rats. Will they one day improve transduction in damaged eyes, and restore lost vision in humans?
Jennifer Sun, MD: Why Ophthalmologists Need Machine Learning
The burden of ophthalmic disease is rising. How can ophthalmologists rise to meet it?
Aflibercept Reverses Nonproliferative Diabetic Retinopathy Progression
Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.
Real-World Study Suggests DME Patients Receive Suboptimal Anti-VEGF Dosing
75% of patients with newly-diagnosed, treatment naïve DME received no treatment within 1 year of diagnosis.
IMCgp100 Highly Effective for Advanced Uveal Melanoma
The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, advanced uveal melanoma.
Voretigene Neparvovec Benefit Sustained at 3 Years for Inherited Retinal Disease
Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.
Real-World Study Highlights Undertreatment of nAMD
Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.
Hopkins Researchers Grow Attendance to Free Eye Care Screens 152% Using Vouchers
Researchers hypothesized that making eye care screens free also reduced perceived value of the services.
Artificial Intelligence Can Predict Retreatment Intervals in nAMD
An automated artificial intelligence-based system was approximately 70% accurate at predicting optimal retreatment intervals for nAMD.
DRCR's Anti-VEGF Treatment Algorithm Improves PDR Outcomes at 2 Years
The majority of eyes treated in the DRCR Protocol S study had resolved, stable or improved NV at each follow-up visit.